"Medical Journeys" is a set of clinical resources reviewed by physicians, meant for the medical team as well as the patients they serve. Each episode of this journey through a disease state contains ...

How do dermatologists diagnose atopic dermatitis? To diagnose atopic dermatitis, also called eczema, a board-certified dermatologist carefully examines your (or your child's) skin and asks questions. ...

A session held at the American Academy of Dermatology Annual Meeting 2024 highlighted the ways in which atopic dermatitis can be treated and addressed in adults and older adults. This content was ...

INDICATIONS ZORYVE cream, 0.05%, is indicated for topical treatment of mild to moderate atopic dermatitis in pediatric patients 2 to 5 years of age. ZORYVE cream, 0.15%, is indicated for topical ...

Please provide your email address to receive an email when new articles are posted on . Pimecrolimus improved six of seven assessed outcomes. Upadacitinib was among the most effective but also most ...

SILVERBERG: As a board-certified dermatologist in an academic referral center, I encounter a substantial caseload of patients with atopic dermatitis and other chronic inflammatory skin conditions.

If you’re a person of color, finding the right treatment for atopic dermatitis, a common form of eczema, can be challenging. Even though the disease is more prevalent in Black Americans than white ...

Maybe your child has been on a specific treatment for atopic dermatitis (also called eczema) for months or even years, but now flare-ups seem to be happening more often and with greater intensity. Or ...

ZORYVE cream 0.05% provides rapid and effective relief of mild to moderate atopic dermatitis in children ages 2 to 5 and is safe and well tolerated Once-daily, steroid-free cream can be used anywhere ...

Positive topline Phase 2b data in atopic dermatitis support amlitelimab as a potential first and best-in-class novel investigational anti-OX40-ligand monoclonal antibody Amlitelimab shows ...

Apogee Therapeutics, Inc.’s APG777 shows best-in-class week-16 efficacy and quarterly/semi-annual dosing potential. In my view, this could give this drug candidate a great competitive profile. In fact ...

Interim clinical data from APG777 Phase 1 healthy volunteers study exceeded all trial objectives and achieved a half-life of approximately 75 days with a potentially best-in-class profile 16-week ...